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ABSTRACT  
Apremilast is used for treatment of psoriasis and psoriatic arthritis. It may also be beneficial for other inflammatory diseases relevant 
to the immune system. The drug functions as a selective enzyme phosphodiesterase 4 (PDE4) inhibitor and avoids the spontaneous 
development of TNF-alpha from human synovial rheumatoid cells. The present review assesses the different approaches for evaluation of 
apremilast in bulk material as well as different formulations. A concise review consists of compile and discuss about over 30 methods for 
analysing apremilast in the biological matrices, the samples of bulk and in different dosage formulations including HPLC, HPTLC, UPLC, LC-MS 
and UV-spectrophotometry. A concise review represents the compilation and discussion of about more than 30 analytical methods which 
includes HPLC, HPTLC, UPLC, LC-MS and UV-Spectrophotometry methods implemented for investigation of apremilast in biological matrices, 
bulk samples and in different dosage formulations. This detailed review will be of great help to the researcher who is working on apremilast.  
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Introduction of Apremilast:  
Chemically, Apremilast is known as N-[2-[(1S)-1-(3-ethoxy-
4methoxyphenyl)-2-(methylsulfonyl) ethyl]-1,3-dioxo-
2,3dihydro-1H-isoindol-4-yl] acetamide. It has a 
C22H24N207S and a molecular weight of 460.5g mole. (1). 
Apremilast is a drug approved by the Food and Drug 
Administration, used for psoriasis and psoriatic arthritis 
treatment. It may also be beneficial for other inflammatory 
diseases related to the immune system. The drug functions 
as a potent phosphodiesterase 4 (PDE4) enzyme inhibitor 
and prevents the spontaneous development of TNF-alpha 
from human synovial rheumatoid cells. (2) Apremilast is 
Phthalimide derivative. It is a white to pale yellow, non-
hygroscopic powder that is virtually insoluble at a wide 
range of pH in water and buffer solutions but is soluble in 
lipophilic solvents including acetonitrile, butanone, acetone, 
dichloromethane, and tetrahydrofuran. It is manufactured in 
India by Glenmark Pharmaceutical, under the brand name 
Otezla and Aprezo (3). Apremilast chemical structure has 
been adequately demonstrated by elemental analysis. IR and 
UV spectroscopy, 1H and 13C NMR spectroscopy, mass 
spectrometry, single crystal X-ray diffraction and XRPD, 
DSC,TGA,DVS and particle size distribution, as well as 
polymorphism system (characterized by XRPD, DSC, TGA, 
DVS, TGA/FT-IR and microscopic testing) Apremilast shows 
stereoisomerism due to the presence of a single chiral centre, 
with the pharmacologically active (S)-enantiomer. Effective 
drug stability tests and clinical studies have shown that 
Apremilast (S)-enantiomer is not interconverted to its (R)-
enantiomer both on storage and in vivo. Polymorphism and 
seven polymorphic forms were observed for Apremilast 
(designated A-G) was named for the active substance. The 
desirable type B was found to be the most anhydrous form of 
Apremilast which is thermodynamically stable. The 
production cycle consistently yields single crystal type B 
active substance. (4) 
 
Fig1. Structure of Apremilast.
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Table 1: Drug profile of Apremilast: 
Drug Name Apremilast  
Category 
Phoshodiesterase4 (PDE4). 
Immunomodulating agent.  
Chemical formula C22H24N2O7S 
IUPAC Name 
N-[2-[(1S)-1-(3ethoxy-4-
methoxyphenyl)-2-
methylsulfonylethyl]-
1,3dioxoisoindol-4-yl] acetamide. 
Molecular weight 460.501 g/mol 
Melting point 156-158℃. 
Solubility 
slightly soluble in water, sparingly 
soluble in Acetonitrile and Methanol. 
Half life 6 - 9 hours 
Pak value 
              Strongest acid- 14.42                        
              Strongest base- 8.91 
log P value 
log P 2.69        
 log P 2.74 
log S value -3.1 
 
 
Mechanism of Action: 
A small molecule of Apremilast is inhibitor of PDE4, an 
enzyme that break down cyclic adenosine monophosphate 
(cAMP), and it’s the dominant enzyme responsible for this 
reaction in inflammatory cells. (5) 
Analytical techniques used for determination of 
apremilast:  
A. High-performance liquid chromatography (HPLC): 
High performance liquid chromatography (HPLC) is one of 
todays most important instrument of analytical chemistry, 
derived from classical column chromatography. The concept 
is to inject a sample solution into a column of a permeable 
material (stationary phase), and pump a liquid (mobile 
phase) through the column at high pressure. The separation 
is based on differences in migration rates across column 
resulting from different sample partition between stationary 
and mobile phase elution happens at different times, 
depends on the separation behaviour of different 
components. (6) 
The HPLC instrument involves pump, injector, column, 
detector, integrator and display system. 
The technique of HPLC has following features. 
 Having higher resolution                                                                                                                                            
 Diameter is small, Stainless steel, Glass column   
 Rapid analysis    
 Mobile phase pressure is higher  
 Mobile phase having controlled flow rate (7) 
Types of HPLC:  
Its Depends on the substance used i.e. stationary phase used, 
the HPLC is divided into following types:  
 Normal Phase HPLC- on the   basis of polarity the 
separation is done. Usually this phase is polar, silica is 
used mostly and Hexane is used as non- polar phase, 
also chloroform and diethyl ether. Mostly the polar 
samples are mounted on column.  
 Reverse Phase HPLC- In this the mobile phase is polar 
and non-polar or hydrophobic is stationary phase. It is 
reverse to normal phase HPLC. The more is the non-
polar nature the more it will be retained on column. 
 Size-exclusion HPLC- The column must combine 
molecules with correctly regulated substrate. The 
constituent’s separation will be based on the 
differences in molecular sizes. 
 Ion-exchange HPLC- The stationary phase has, across to 
the sample charge, an ionically charged surface. The 
used mobile phase is an aqueous buffer that regulates 
pH and ionic strength. (8) 
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Table 2: HPLC method for apremilast 
Sr. 
no. 
Drug Method Stationary 
phase 
Mobile 
phase 
Detection/Detector Linearity, 
LOD, LOQ 
(µg/mL) 
Rt / FR Ref 
1 Apremilast HPLC 
(stability 
indicating, 
RS) 
Cosmosil C-18 
column 250 mm 
x 4.6 mm, 5.0 μm 
with Guard 
cartridge: Make; 
Phenomenex 
C18, 4.0 mm x 
3.0 mm 
Mobile 
Phase-A: 
Buffer-1: 
Methanol 
(90:10) v/v 
Mobile 
Phase-B: 
Buffer-1: 
Acetonitrile 
(10:90) v/v 
 
230nm. 
PDA Detector 
 
Linearity: 
50% to 150% 
LOD:0.0012% 
LOQ:0.004% 
 
 
Rt: 1min 
 
FR: 1 
ml/min 
 
 
1 
2 Apremilast RP-HPLC Grace C18 
column 
(250mm×4.6, 
Particle size:5 
micron) 
 
 
Methanol: 
Water 
(80:20) 
231nm 
UV 2450 Double 
Beam UV-Visible 
spectrometer 
Linearity: 10-
50 µg/mL 
LOD: - 
LOQ: - 
Rt: 
4.80min 
 
FR: 0.8 
ml/min 
 
3 
3 Apremilast HPLC Agilent C 18 (4.6 
mm 250 mm.), 
5µm 
 
Acetonitrile: 
Water 
(70:30) 
 
 
230nm 
 
Linearity: 2-
10 µg/mL 
LOD:   0.2403 
LOQ: 0.72084 
Rt: 
4.92min 
 
FR: - 
ml/min 
 
5 
4 Apremilast RP-HPLC Ultima C18 
column (250 
mm×4.6 mm, i.d., 
5 am particle 
size) 
Methanol: 
Water 
(70:30) 
231nm 
Photo Diode Array 
 
- 
Rt: 
5.15min 
 
FR: 1 
ml/min 
 
24 
5 Apremilast RP-LC 
(stability 
indicating) 
Synergi Max-RP 
80 A (150 × 4.6 
mm ID), 4 µ 
Mobile phase 
A: Phosphate 
Buffer 
Mobile Phase 
B: ACN 
230 nm 
photodiode array 
detector 
Linearity : 
50% - 250% 
LOD: - 0.053 
μg/ml-1 
LOQ: - 0.160 
μg/ml-1 
Rt : 
13.66min 
 
FR: 1 
ml/min 
 
25 
 
 
B. UV- visible spectrophotometric method: 
UV-Visible spectrophotometry is mostly used method in 
pharmaceutical research. This means calculating how much 
ultraviolet or visible radiation a material absorbs in solution. 
Ultraviolet-Visible spectrophotometers are the instruments 
that compute the correlation or function of the correlation of 
the intensity of two light beams in the UV-Visible region. 
Using a spectrophotometer, organic compounds can be 
detected in qualitative analysis, if any reported data are 
available, and significant spectrophotometric examination is 
used to determine the amount of molecular species 
absorbing the radiation. Spectrophotometric technique is 
simple, fast, relatively precise, and applicable to small 
compound quantities. The Beer-Lambert law is the 
fundamental law governing quantitative spectrophotometric 
analysis. 
Beer's law: It states that the intensity of a parallel monochro
matic radiation beam decreases exponentially with the numb
er of molecules that are absorbed. To put it another way, abs
orbance is proportionate to concentration. 
Lambert's law: It states that the frequency of a parallel mono
chromatic radiation beam diminishes exponentially as it trav
els through a homogeneous thickness medium. Combining th
ese two laws gives rise to the Beer-Lambert law. 
Table 3: Regions of electromagnetic spectrum. 
Region  Wavelength  
Far (or vacuum) ultraviolet  10-200 nm  
Near ultraviolet  200-400 nm  
Visible  400-750 nm  
Near infrared  0.75- 2.2 μm 
Mid infrared  2.5-50 μm 
Far infrared  50-1000 μm 
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Beer-Lambert law:  
If light beam is passed through a translucent 
cell containing an an absorbing compound solution, there ma
y be a decrease in light intensity. The BeerLambert Law is ex
pressed in mathematical terms as 
 A = a b c  
 Where, 
 A = absorbance or optical density   
 a = absorptivity or extinction coefficient 
 b = path length of radiation through sample (cm)  
 c = concentration of solute in solution.  
Both b and a are constant so a is directly proportional to the 
concentration c. (9) 
 
Table 4: UV- Spectrometric Method for Apremilast. 
Sr. 
No. 
Drug Matrix Method Solvent Detection Linearity/ LOD, LOQ Ref. 
1 Apremilast API  A double beam UV-
visible 
spectrophotometer 
Water and 
Methanol 
230 nm Linearity: 2-10 µg/mL 
R2 :0.999 
LOD: --µg/mL 
LOQ: --µg/mL 
 
 
28 
2 Apremilast Bulk and 
laboratory 
prepared 
mixture. 
A double beam UV 
1700 Pharmaspec 
Methanol Method A: 
230 nm 
Method B: 
224nm 
Method C: 
225-
235nm 
Linearity: 4-12µg/mL 
R2 :Method A(0.9988) 
Method B:( 0.992)   
Method C (0.9993) 
LOD:    Method A  0.36 
µg/mL Method B  0.35 
µg/mL Method C  0.33 
µg/mL  
LOQ: Method A  1.08 
µg/mL Method B  1.07 
µg/mL Method C  1.00 
µg/mL                                                   
 
 
29 
3 Apremilast Bulk and 
Tablet 
Dosage 
Form 
UV- 
Spectrophotometer 
(Systronic-2201) 
Acetonitrile  230 nm Linearity: 2-10µg/mL 
R2 : 0.9995 
LOD: 0.2403µg/ML 
LOQ: 0.72084µg/mL 
 
  30 
 
4 Apremilast Bulk drug Jasco double beam 
UV-visible 
spectrophotometer, 
Model: V-630 
Methanol. 230 nm  Linearity: 1-7 µg/ml. R2 : 
0.9991 
LOD: 0.288µg/mL 
LOQ: 0.874 µg/mL 
 
31 
 
C. High performance thin layer chromatography 
(HPTLC): 
Modern TLC, which carried out on pre-coated layers with 
instruments and mainly for quantification is widely 
understood and practical as HPTLC. Therefore, TLC and 
HPLC terminology are used interchangeably here. To teach 
the principal of chromatography, almost all over the world, 
TLC is used. The prime reasons for this preference are 
transparency of the sample during chromatography, 
simplicity to perform, and ultra-low-cost equipment for 
demonstration. A popular approach for increase resolution 
under capillary flow-controlled conditions is to use various 
developments. For planar chromatography, either one-
dimensional or two-dimensional separations are possible. 
Mobile phase velocity can also be manage by external 
method, such as in forced-flow development. HPTLC is the 
fastest form of chromatography, since sample 
chromatography is performed in parallel. Being offline, i.e. 
each step of the process is carried out independently, makes 
TLC / HPTLC not only faster but also versatile adequate for 
one HPTLC system to analyse individual samples by side by 
side.  Stationary and mobile phase intake is directly 
proportional to the number of analysed samples. 
 The cost for analysis is low. One 20x10 cm plate can accept 
about 20 samples and needs a mobile phase of 15 ml. For 
TLC / HPTLC the disposable stationary process has two 
distinct advantages in the preparation of samples. One 
sample can be washed on the plate itself. The other is that 
sample cleaning may not be necessary because the residual 
residue is inconsistent. Although the Silica gel is the most 
commonly used adsorbent (stationary phase), many other 
adsorbents have been used as a separation medium such as 
reverse phases, bonding phases, alumina, Kieselguhr, etc. 
Some solvents can be used during the mobile phase since the 
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coating can be disposed of. Gas phase also plays a prime role 
in TLC/HPTLC in the developing chamber’s vapor saturation, 
its pH, and humidity in the developing chamber.  
For quantitative, semi-quantitative and qualitative analysis, 
TLC and HPTLC may be used. It can also be used after 
chromatographic separation for the identification of 
industrial fractions and for the identification of herbal 
extracts, complex mixtures by “HPTLC fingerprint”. Many 
laboratories use TLC/HPTLC for the analysis, checking or 
comparison of impurities with related samples, screening of 
unidentified   samples. TLC / HPTLC is a functional    tool for 
daily analysis: quality control, scientific R&D, process 
monitoring and environmental laboratories. (10-13)
 
Table 5: HPTLC method for apremilast. 
Sr. 
no 
Drug and 
Matrix 
Stationary 
phase 
Mobile phase Chamber 
saturation/ TLC 
plate 
development 
time 
Detection Linearity, LOD, 
LOQ 
(µg/mL) 
Ref. 
1 Apremilast 
(Bulk and in-
house tablet) 
Aluminium 
backed 
precoated silica 
gel 60-F254 (20 
x 10 cm) 
Toluene: 
Methanol (8:2 
v/v) 
CSt: 25min 
PDt: 8min 
Rf value:  0.64 ± 
0.05 
Densitometry 
scanning at 
230nm 
Linearity:    250-
1500 ng/band 
R2: 0.998 
LOD- (DL) 3.3NB 
LOQ- 
(QL) 10NB 
 
26 
2 Apremilast Aluminium TLC 
plate precoated 
with silica gel 60 
F254 (10 x 10 
cm) 
Toluene: Ethyl 
Acetate 
(4:6v/v) 
CSt: 15min 
PDt: 10min 
Rf value:  
0.55±0.02. 
Densitometry 
scanning at 
236nm 
Linearity:    100-
600 ng/band 
R2: 0.9978 
LOD-
0.7782ng/band 
LOQ- 
2.3583ng/band 
 
27 
 
D. Stability indicating method: 
Chemical stability of pharmaceutical substances is of great 
concern, as it influences the drug product's safety and 
effectiveness. The FDA and ICH guidelines state the need for 
stability testing data to determine how the nature of a drug 
substance and drug product changes over time under the 
effect of different environmental factors. The ICH guideline 
notes that stress testing is intended to identify the likely 
degradation products which further assist in determining 
the molecule's intrinsic stability and identifying pathways of 
degradation, and confirm the stabilization indicating 
procedures used. (14-15) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Scheme 1:  An illustrative flowchart describing various stress conditions used for degradation of drug substance and drug 
product. 
 
Force degradation study  
Drug substance  Drug product  
Solid  Solution/ 
suspension 
Photolytic 
Thermal 
Thermal/Humidity  
Acid/ Base Hydrolysis  
Oxidative  
Solid Semisolid 
Photolytic 
Thermal 
Thermal/Humidity 
Oxidative  
Photolytic 
Thermal 
Thermal/Humidity 
Solution/ 
suspension 
Photolytic 
Thermal 
Oxidative  
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Table 6: Conditions generally employed for forced degradation (16). 
Degradation Type Experimental Conditions Storage Conditions Sampling Time (days) 
Hydrolysis Control API (no acid or base) 40℃, 60 ℃ 1,3,5 Days 
0.1 N HCl 40℃, 60 ℃ 1,3,5 Days 
0.1 N NaOH 40℃, 60 ℃ 1,3,5 Days 
Acid control (no API) 40℃, 60 ℃ 1,3,5 Days 
Base control (no API) 40℃, 60 ℃ 1,3,5 Days 
pH: 2,4,6,8 40℃, 60 ℃ 1,3,5 Days 
Oxidation 3% H2O2 25℃, 60℃ 1,3,5 Days 
Peroxide control 25℃, 60℃ 1,3,5 Days 
Azobisisobutyronitrile (AIBN) 40℃, 60 ℃ 1,3,5 Days 
AIBN control 40℃, 60 ℃ 1,3,5 Days 
Photolytic Light, 1 X ICH NA 1,3,5 Days 
Light, 3 X ICH NA 1,3,5 Days 
Light control NA 1,3,5 Days 
Thermal Heat chamber 60℃ 1,3,5 Days 
Heat chamber 60℃/75% RH 1,3,5 Days 
Heat chamber 80℃ 1,3,5 Days 
Heat chamber 80 ℃/75% RH 1,3,5 Days 
Heat control Room temp. 1,3,5 Days 
 
Table 7: stability indicating method for Apremilast 
Sr. 
no. 
Drug Method Stationary 
phase 
Mobile 
phase/ 
Solvent 
Detection/Detector Linearity, 
LOD, LOQ 
(µg/mL) 
Rt / FR Ref. 
1 Apremilast RP-HPLC 
 
Grace C18 
(250mm x 
4.6ID, 5μm) 
Methanol: 
Water 
(70:30) 
230nm 
UV-3000-M detector 
Linearity: 10-
50μg/ml 
LOD: - 0.5329 
μg/ml 
LOQ: - 1.615 
μg/ml 
Rt : 5.20min 
 
FR: -0.8 
ml/min 
 
34 
2 Apremilast RP-HPLC Inertsil C8 
(250 X 4.6 
mm) 5µ 
Buffer and 
Methanol 
(47:53 % 
v/v) 
230nm Diode      
array detector 
 
- 
Rt: 8.3min 
 
FR: -1.5 
ml/min 
35 
3 Apremilast UV - Acetonitrile 229.3 nm 
ELICO Double beam 
SL 210 Ultra violet - 
Visible 
spectrophotometer 
Linearity: 2-
10µg/mL 
R2 : 0.9983 
LOD: 
0.0027µg/mL 
LOQ: 
0.0082µg/mL 
-  
 
36 
4 Apremilast UV - Methanol. 220 nm 
Methanol. UV – 
Visible 
spectrophotometer 
(Shimadzu Model 
1700) 
Linearity: 20-
100µg/ml 
R2 : 0.999 
LOD: --µg/mL 
LOQ: --µg/mL 
-  
37 
 
 
 
Khadse et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2020; 10(2-s):175-182 
ISSN: 2250-1177                                                                                  [181]                                                                                 CODEN (USA): JDDTAO 
E. Bio-analytical method:  
Bioanalysis is a process used to evaluate concentrations in bi
ological samples such as blood, plasma, serum cerebrospinal 
fluids and urine, as well as saliva for their metabolites and/o
r endogenic substances. (17-20) The accuracy of these trials 
depends directly on the standard of the bioanalytical data 
behind them.  It is therefore important that guiding 
principles are organize and disseminated to the 
pharmaceutical community for the validation of these 
analytical methods. For bioanalysis of drug in plasma Both 
RP - HPLC and LC MS-MS can be used. The   instruments 
have its own merits. For evaluation of a lot of compounds RP 
- HPLC coupled with UV, PDA or fluorescence detector. 
These chromatographic principles give main advantages 
including low detection limits, the potential to produce 
structural information, a need for least sample treatment 
and the probability to cover a broad range of polarity 
analytes, all procedures for validating the bioanalytical 
methods include procedures that show that a certain 
process is used to measure the analytes quantitatively. 
Selectivity, precision, linearity, detection limit, quantity limit, 
recovery, power, stability and range are main parameters for 
this validation. (21-22) 
 The process by which routine sample analysis can be 
classify into: 
1. Reference standard preparation,  
2. Development of bioanalytical method and formation of 
assay procedure and  
3. For routine drug analysis. Application of validated 
bioanalytical method and acceptance criteria for the 
analytical run and/or batch (23). 
 
Table 8: Bioanalytical method for Apremilast. 
Sr.no Method Drug Bio-
fluid 
Column Mob. phase F.R and 
R. T 
Detection 
/detector 
Linearity & 
LOD&LOQ 
Ref. 
1 UPLC/MS-
MS 
Apremilast Rat 
plasma 
Acquity 
BEHTM 
C18 
column 
(100 × 2.1 
mm, 1.7 
μm) 
Acetonitrile: 
ammonia(85:15) 
 
F.R : 0.3 
mL/min 
R.T 
:0.81 
MRM 
detection 
Linearity: 
3.04 and 
1000 ng/ml 
R2 : 0.995 
LOD: - 
LLOQ: 3.04 
ng/ml 
 
32 
2 UPLC/MS-
MS 
Apremilast 
 
Rat 
plasma 
Acquity 
BEH 
C18column 
(2.1 
mm×50 
mm, 1.7 
μm 
particle 
size) 
Solvent -A (0.1% 
formic acid in 
water) 
Solvent B – 
acetonitrile 
F.R : 
0.40 
mL/min 
R.T : - 
XEVO TQD 
triple 
quadruple 
mass 
spectrometer  
with an 
electro-spray 
ionization 
(ESI) 
Linearity: 0.1 
and 100 
ng/ml 
R2 : 0.9914 
LOD: - 
LLOQ: 
0.1ng/ml 
 
33 
 
Conclusion  
The present review illustrates various analytical approaches 
exercised for the evaluation of Apremilast. A numerous 
investigation had perform including, Bio-analytical, Stability 
indicating, HPLC, HPTLC, UV-Visible Spectroscopy, and LC-
MS, etc. for evaluation of Apremilast in bulk and in its 
combined pharmaceutical formulations and in plasma. 
Liquid chromatography with UV detection has been found to 
be most studied for Apremilast in bulk as well as 
pharmaceutical dosage forms, while hyphenated such as LC-
MS methods are reported for determination of Apremilast 
and its metabolite in plasma and other biological fluids. Few 
chromatography approaches like HPTLC and UV 
Spectrophotometry methods are also used for assay of 
Apremilast. 
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